STOCK TITAN

Senseonics Holdings Inc - SENS STOCK NEWS

Welcome to our dedicated news page for Senseonics Holdings (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Senseonics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Senseonics Holdings's position in the market.

Rhea-AI Summary
Ascensia Diabetes Care and Senseonics Holdings announce an extension of the Eversense Payment Assistance and Simple Savings Program, offering eligible individuals in the U.S. the Eversense E3 CGM System for just $200 per year. The program allows individuals to pay $99 out of pocket for each 6-month system, providing significant savings for continuous glucose monitoring. This initiative aims to make long-term CGM more accessible and affordable for people with diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
-
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) announces data from the Eversense Post Approval Study to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Italy. Dr. Kashif Latif to present People Reported Outcomes from the U.S. study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
none
-
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) to participate in Oppenheimer Healthcare MedTech & Services Conference. The company focuses on long-term, implantable continuous glucose monitoring systems for diabetes patients. The management will present on March 13, 2024, at 12:00pm ET. Interested parties can access the webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
conferences
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) reported strong financial results for Q4 2023, with revenue of $8.0 million, a 44% increase from the previous year. Full-year revenue reached $22.4 million, a 37% growth compared to 2022. The company completed the ENHANCE pivotal trial for the 365-day Eversense system, with an FDA regulatory filing expected soon. Medicare expanded access to the Eversense E3 CGM System, and Brian Hansen was appointed President of CGM at Ascensia Diabetes Care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.47%
Tags
earnings
-
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) will release its Q4 and full year 2023 financial results on February 29, 2024. A conference call will be held to review the performance, with a webcast available on the company's website. Investors and analysts can dial in to listen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.07%
Tags
earnings
-
Rhea-AI Summary
Ascensia Diabetes Care and Senseonics Holdings, Inc. announce Medicare expansion for Eversense E3 CGM System, providing access to all people with diabetes using insulin and non-insulin users with hypoglycemia history. The Eversense E3 offers unique features like up to 6-month sensor wear duration, high accuracy, removable transmitter, and predictive alerts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.34%
Tags
none
Rhea-AI Summary
PHC Holdings Corporation and Senseonics Holdings, Inc. announced the appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care, reinforcing their commitment to diabetes innovation. Hansen will be responsible for global commercialization and growth of the Eversense CGM, offering unique features such as a fully implantable system, long-term glucose measurement, and a removable smart transmitter. The partnership aims to drive patient and provider adoption of Eversense, with a focus on delivering breakthrough diabetes devices to empower people living with diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
management
-
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) announces operational and financial business updates, including preliminary unaudited fourth quarter revenue of $8.0 million and full year 2023 total revenue of $22.0 million. The company completed data analysis of ENHANCE trial and plans to submit an application for regulatory approval to the FDA for a 365-day once per week calibration product by the end of the first quarter of 2024. The company also closed an additional $10.0 million draw on the loan facility with Hercules Capital, Inc. in the fourth quarter, with unaudited balance of cash, cash equivalents, and marketable securities as of December 31, 2023, expected to be approximately $109.8 million. The company expects to provide financial guidance for 2024 with the full fiscal year 2023 financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
none
-
Rhea-AI Summary
Senseonics Holdings, Inc. (NYSE American: SENS) reported Q3 2023 financial results, including $6.1M in revenue, completion of a pivotal clinical study, and a new advertising campaign. Gross profit increased to $1.2M, while net loss decreased to $24.1M. The company expects full year 2023 global net revenue to be in the range of $20M to $24M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
earnings
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) to Participate in Stifel 2023 Healthcare Conference, Presenting on Long-Term Implantable CGM Systems for Diabetes Patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
conferences
Senseonics Holdings Inc

NYSE:SENS

SENS Rankings

SENS Stock Data

281.84M
506.10M
6.38%
12.46%
7.94%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Germantown

About SENS

senseonics, inc. is a medical device startup company in germantown, maryland, usa (near washington, dc) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. utilizing breakthrough fluorescence sensing technology, the senseonics continuous glucose monitoring ("cgm"​) system is being designed to be the first fully implantable cgm that is highly accurate and stable throughout its long sensor life. the system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.